

Regulatory Secretariat Division, by calling 202-501-4755 or emailing [GSARegSec@gsa.gov](mailto:GSARegSec@gsa.gov). Please cite OMB Control No. 9000-0082, Federal Acquisition Regulation Part 7 Requirements.

**Janet Fry,**

*Director, Federal Acquisition Policy Division, Office of Governmentwide Acquisition Policy, Office of Acquisition Policy, Office of Governmentwide Policy.*

[FR Doc. 2022-06992 Filed 4-1-22; 8:45 am]

**BILLING CODE 6820-EP-P**

## GOVERNMENT ACCOUNTABILITY OFFICE

### Request for Nominations for the Board of Governors of the Patient-Centered Outcomes Research Institute (PCORI)

**AGENCY:** Government Accountability Office (GAO).

**ACTION:** Request for letters of nomination and resumes.

**SUMMARY:** The Patient Protection and Affordable Care Act gave the Comptroller General of the United States responsibility for appointing up to 21 members to the Board of Governors of the Patient-Centered Outcomes Research Institute. In addition, the Directors of the Agency for Healthcare Research and Quality and the National Institutes of Health, or their designees, are members of the Board. As the result of terms ending in September 2022, GAO is accepting nominations in the following categories: A surgeon, a state-licensed integrative health care practitioner, a representative of patients and health care consumers, a representative of device manufacturers or developers, a representative of pharmaceutical manufacturers or developers, and a representative of private payers who represents health insurance issuers. Nominations should be sent to the email address listed below. Acknowledgement of submissions will be provided within a week of submission.

**DATES:** Letters of nomination and resumes should be submitted no later than May 10, 2022, to ensure adequate opportunity for review and consideration of nominees prior to appointment.

**ADDRESSES:** Submit letters of nomination and resumes to [PCORI@gao.gov](mailto:PCORI@gao.gov). Include PCORI Nomination in the subject line of the email.

**FOR FURTHER INFORMATION CONTACT:** Ray Sendejas at (202) 512-7113 or [SendejasR@gao.gov](mailto:SendejasR@gao.gov) if you do not receive an acknowledgement or need

additional information. For general information, contact GAO's Office of Public Affairs, (202) 512-4800.

*Authority:* Sec. 6301 and Sec. 10602, Pub. L. 111-148, 124 Stat. 119, 727, 1005 (2010); Div. N, Sec. 104, Pub. L. 116-94, 133 Stat. 2534 (2019).

**Gene L. Dodaro,**

*Comptroller General of the United States.*

[FR Doc. 2022-06452 Filed 4-1-22; 8:45 am]

**BILLING CODE 1610-02-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket No. CDC-2022-0044]

### CDC Recommendations for Hepatitis B Screening and Testing—United States, 2022; Request for Comment

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice with comment period.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the opening of a docket to obtain comment on proposed updated recommendations for hepatitis B virus (HBV) infection screening and testing (Proposed Updated Recommendations), including hepatitis B screening at least once in a lifetime for persons 18 years of age and older, using a three-test panel. The Proposed Updated Recommendations also expand existing risk-based testing recommendations to include the following populations, activities, exposures, or conditions associated with increased risk for HBV infection: Persons currently or formerly incarcerated in a jail, prison, or other detention setting; persons with a history of sexually transmitted infections or multiple sex partners; and persons with a history of hepatitis C virus infection. The Proposed Updated Recommendations are intended to inform the practices of and care by U.S. healthcare providers and are based on scientific evidence of the effectiveness and economic value of screening to diagnose current HBV infection among adults in the United States.

**DATES:** Written comments must be received on or before June 3, 2022.

**ADDRESSES:** You may submit comments, identified by Docket No. CDC-2022-0044, by either of the following methods:

- *Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments.

- *Mail:* Division of Viral Hepatitis, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop U12-3, Atlanta, GA 30329, Attn: Docket No. CDC-2022-0044.

*Instructions:* All submissions received must include the agency name and Docket Number. All relevant comments received will be posted without change to <http://www.regulations.gov>, including any personal information provided. Do not submit comments by email; CDC does not accept comments by email. For access to the docket to read background documents or comments received, go to <http://www.regulations.gov>.

**FOR FURTHER INFORMATION CONTACT:** Erin Conners, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop U12-3, Atlanta, GA 30329; Telephone: 404-639-8000; Email: [DVHpolicy@cdc.gov](mailto:DVHpolicy@cdc.gov).

#### SUPPLEMENTARY INFORMATION:

##### Public Participation

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to any of the Proposed Updated Recommendations or supporting evidence. In addition, CDC invites comments specifically on the following questions:

- Based on the evidence presented in the full recommendations document (see the Supporting and Related Materials tab in the docket), does the evidence support the Proposed Updated Recommendations for HBV infection screening and testing? If not, please state the reason why and, if available, provide additional evidence for consideration.

- Are CDC's Proposed Updated Recommendations (see Supporting and Related Materials) clearly written? If not, what changes do you propose to make them clearer?

- If implemented as currently drafted, do you believe the Proposed Updated Recommendations would result in a reduction in HBV infections and associated health and financial consequences (e.g., patient and healthcare costs to treat chronic hepatitis B) in the United States? If not, please provide an explanation and supporting data or evidence.

Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on <https://www.regulations.gov>. Therefore, do not include any information in your